

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 May 2023 (25.05.2023)



(10) International Publication Number
WO 2023/092062 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 7/02 (2006.01)
A61K 9/08 (2006.01) C07K 16/36 (2006.01)

(21) International Application Number:

PCT/US2022/080131

(22) International Filing Date:

18 November 2022 (18.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/281,024 18 November 2021 (18.11.2021) US
63/287,633 09 December 2021 (09.12.2021) US
63/355,314 24 June 2022 (24.06.2022) US

(71) Applicant: ANTHOS THERAPEUTICS, INC. [US/US];
55 Cambridge Parkway, Cambridge, Massachusetts 02142
(US).

(72) Inventors: FREEDHOLM, Debra A.; c/o 55 Cambridge Parkway, Cambridge, Massachusetts 02142 (US).
BLOOMFIELD, Daniel M.; 212 8TH AVE, Belmar, New Jersey 07719 (US). GLASSPOOL, Royston J.; c/o 55 Cambridge Parkway, Cambridge, Massachusetts 02142 (US). FREEMAN, Jonathan E.; c/o 55 Cambridge Parkway, Cambridge, Massachusetts 02142 (US).

way, Cambridge, Massachusetts 02142 (US). KHDR, Yasser; 3 Rue des Paquerettes, 68128 Rosenau (FR).

(74) Agent: HENDRICK, Natalie; Goodwin Procter LLP, 100 Northern Avenue, IP DOCKETING DEPT./7TH FL, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: DOSING REGIMENS OF FACTOR XI/XIA ANTIBODIES

Graft Thrombus

Collagen




FIG. 5A

(57) Abstract: This disclosure relates to dosage regimens for anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies or antigen-binding fragments thereof, pharmaceutical formulations comprising the same, and pharmaceutical formulations for use in the treatment of thromboembolic disorders or related conditions. Also provided are pharmaceutical formulations of anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof. Also provided are methods of treating patients having thrombocytopenias with anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof.

WO 2023/092062 A1

[Continued on next page]

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*